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Specific SSRIs and birth defects: bayesian analysis to interpret 
new data in the context of previous reports
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ABSTRACT
ObjeCtive
To follow up on previously reported associations 
between periconceptional use of selective serotonin 
reuptake inhibitors (SSRIs) and specific birth defects 
using an expanded dataset from the National Birth 
Defects Prevention Study.
Design
Bayesian analysis combining results from independent 
published analyses with data from a multicenter 
population based case-control study of birth defects.
setting
10 centers in the United States.
PartiCiPants
 17 952 mothers of infants with birth defects and 9857 
mothers of infants without birth defects, identified 
through birth certificates or birth hospitals, with 
estimated dates of delivery between 1997 and 2009.
exPOsures
Citalopram, escitalopram, fluoxetine, paroxetine, or 
sertraline use in the month before through the third 
month of pregnancy. Posterior odds ratio estimates 
were adjusted to account for maternal race/ethnicity, 
education, smoking, and prepregnancy obesity.
Main OutCOMe Measure
 14 birth defects categories that had associations with 
SSRIs reported in the literature.
results
Sertraline was the most commonly reported SSRI, but 
none of the five previously reported birth defects 
associations with sertraline was confirmed. For nine 
previously reported associations between maternal 
SSRI use and birth defect in infants, findings were 
consistent with no association. High posterior odds 
ratios excluding the null value were observed for five 
birth defects with paroxetine (anencephaly 3.2, 95% 
credible interval 1.6 to 6.2; atrial septal defects 1.8, 1.1 
to 3.0; right ventricular outflow tract obstruction 
defects 2.4, 1.4 to 3.9; gastroschisis 2.5, 1.2 to 4.8; 
and omphalocele 3.5, 1.3 to 8.0) and for two 
defects with fluoxetine (right ventricular outflow 
tract obstruction defects 2.0, 1.4 to 3.1 and 
craniosynostosis 1.9, 1.1 to 3.0).
COnClusiOns
These data provide reassuring evidence for some 
SSRIs but suggest that some birth defects occur 2-3.5 
times more frequently among the infants of women 
treated with paroxetine or fluoxetine early in 
pregnancy. 
Introduction
The association between maternal use of antidepres-
sants, especially selective serotonin reuptake inhibitors 
(SSRIs), during pregnancy and birth defects in the infants 
has been the topic of much discussion in recent years. 
After initial reports of an association between paroxetine 
and heart defects, the US Food and Drug Administration 
published an advisory warning of this potential asso-
ciation in December 2005.1  Recent meta-analyses and 
systematic reviews combining data from more than 20 
epidemiological studies have reached conflicting conclu-
sions and this uncertainty influences perceptions of the 
safety of antidepressant use in pregnancy.2 3  In a recent 
study, 69% of women thought that it was definitely or 
probably acceptable to take such drugs when not preg-
nant or breast feeding, but only 33% of women thought 
that it was definitely or probably acceptable to do so when 
pregnant.4  SSRIs are increasingly used by women of 
reproductive age and during pregnancy, but the inconsis-
tent reports have limited opportunities for clinicians to 
carefully evaluate the risk compared with benefit of spe-
cific SSRIs for a given patient during pregnancy.5-7
We reviewed the literature for any reports that 
assessed the relation between specific SSRIs and one or 
more of the specific birth defects that are also included 
in the US National Birth Defects Prevention Study 
(NBDPS).2 8-13 To provide a more robust estimate of the 
association between individual SSRIs and birth defects, 
information that is necessary for decision making by 
patients who are being treated with these drugs and 
their physicians, we used bayesian methods both to 
summarize independent findings identified in the liter-
ature and to update those findings using the entire set 
of data from the NBDPS.14
Methods
study population
For this analysis we used data from the NBDPS, a popu-
lation based case-control study of birth defects. The 
study’s methods have been described previously.15-17 
Briefly, cases of birth defects were identified through 
birth defects surveillance systems in the US states of 
Arkansas, California, Georgia, Iowa, Massachusetts, 
WhAT IS AlReAdy knoWn on ThIS TopIC
Selective serotonin reuptake inhibitors (SSRIs) are increasingly used by women of 
reproductive age and during pregnancy
However, inconsistent reports on the association with birth defects have limited 
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specific SSRIs during pregnancy
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New Jersey, New York, North Carolina, Texas, and Utah. 
Cases could be live born, stillborn, or induced abortions 
with one of over 30 major birth defects. The NBDPS 
excluded cases with known chromosomal or mono-
genic disorders. Unmatched liveborn controls from the 
same geographical region and time period were 
selected from birth certificates or birth hospital records. 
More cases than controls were included overall because 
the study was designed for the assessment of individual 
defects, where controls, which were the same for all 
case groups, outnumbered even the largest case group. 
Mothers were asked to participate in a telephone inter-
view in English or Spanish between six weeks and two 
years after the estimated date of delivery.
For this analysis we included cases and controls if they 
were born on or after 1 October 1997 and had an esti-
mated date of delivery on or before 31 December 2009. 
Overall participation was 67.4% for cases and 64.8% for 
controls. A previous NBDPS analysis of the association 
between SSRI use during pregnancy and birth defects, 
included in table 1  as Alwan and  colleagues, included 
data from 1997 to 2002.8  To avoid double counting, these 
NBDPS data were excluded from the meta-analyses used 
to calculate prior odds ratios in the current study, but we 
used significant findings from the previous analysis 
along with those of the other studies listed in table 1 to 
determine which birth defect-SSRI combinations to 
assess. Because of the strong association between diabe-
tes and birth defects, we excluded case and control moth-
ers who reported pregestational diabetes (type 1 or 
type 2).18  We also excluded mothers who reported the use 
of any of the following known teratogenic treatments: 
misoprostol, methotrexate, mycophenolate mofetil, tha-
lidomide, or isotretinoin.19
ssri use
During the interview for the NBDPS, no specific question 
addressed depression. Mothers were asked if they had 
any illnesses other than the ones already discussed (for 
example, hypertension or diabetes) and whether they 
took any medication for the illness. Women could report 
depression here, which would then be followed by a 
question about any medications taken for the illness. 
There were also specific medication related questions: 
“between three months before conception and [the 
baby’s] date of birth, did you take any of the following 
medications? Prozac? Paxil? Zoloft? Celexa?” There was 
no specific question for Lexapro. For this analysis, we 
considered women exposed if they reported taking cit-
alopram (Celexa), escitalopram (Lexapro), fluoxetine 
(Prozac), paroxetine (Paxil), or sertraline (Zoloft) at 
least once in the period from one month before 
 conception through the third month of pregnancy. 
Women who reported taking more than one type of SSRI 
were only included in the multiple SSRI category. We 
considered women as unexposed if they did not take 
any antidepressants in the period from three months 
before to the end of the pregnancy and did not report 
any depression, anxiety, bipolar disorder, or obsessive 
compulsive disorder. Women who did not answer all 
medication related questions, used SSRIs in a period 
other than the period of interest, or took antidepres-
sants other than SSRIs (for example, bupropion and 
venlafaxine) were excluded.
birth defects
The NBDPS includes over 30 categories of major birth 
defects. After ascertainment in population based sur-
veillance systems, the diagnostic information was 
table 1 | Previous studies that assessed use of individual selective serotonin reuptake inhibitors (ssris) during early pregnancy in mother 
and individual birth defects in infant
authors study design
Controls/
comparison group Population
included birth 
years ssris
birth defect 
categories 
assessed included confounders
Alwan et al 
20078
Case-control 
(subset of 
current study)
Liveborn infants 
without major 
defects
10 sites in USA 1997-2002 Fluoxetine, 
paroxetine, sertraline
All defects, with at 
least three exposed
Race/ethnicity, obesity, 
smoking, income
Louik et al 
200711
Case-control Non-malformed 
infants
Boston, 
Philadelphia, 
Toronto, San Diego, 
New York State
1993-2004 Citalopram, 
fluoxetine, 
paroxetine, sertraline
All defects Maternal age, race/ethnicity, 
education, year of last 
menstrual period, study 
center, smoking, alcohol, 
family history, body mass 
index, parity, seizures, 
diabetes, infertility, 
hypertension, folic acid use 
Bakker et al 
20109
Case-control Fetuses and children 
with chromosomal 
or single gene 
disorder
Population based 
birth defects 
registry in Northern 
Netherlands
1997-2006 Paroxetine Heart defects 
categories
Year of birth
Kornum et al 
201010
Cohort Children of women 
without SSRI 
prescription
Northern Denmark 1991-2007 Citalopram, 
escitalopram, 
fluoxetine, 
paroxetine, sertraline
Septal heart 
defects
Smoking, age, birth order, 
birth year
Reis and Kallen 
201013
Cohort Children of women 
without 
antidepressant use
Sweden 1995-2007 Citalopram, 
fluoxetine, 
paroxetine, sertraline
Hypospadias Year of birth, age, parity, 
smoking and body mass index
Malm et al 
201112
Cohort Children of women 
without SSRI 
prescription 
reimbursements
Finland 1996-2006 Citalopram, 
escitalopram, 
fluoxetine, 
paroxetine, sertraline
All defects Age, parity, year of birth, 
marital status, smoking, other 
psychiatric medicines, 
diabetes
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reviewed by clinical geneticists at each site to establish 
eligibility. Designated individual clinical geneticists 
reviewed all cases with a particular defect to ensure 
consistency across sites.16  Because the primary intent 
of this analysis was to assess previously reported asso-
ciations with SSRIs and to determine if those associa-
tions were supported by NBDPS data, we included only 
outcomes with at least one previous report in the peer 
reviewed literature suggesting a possible association 
with SSRIs: neural tube defects (international classifica-
tion of diseases, ninth revision (ICD-9): 740-742.0), anen-
cephaly (ICD-9: 740), all septal defects (ICD-9: 745), 
ventricular septal defects (ICD-9: 745.4), right ventricular 
outflow tract obstructions (ICD-9: 746.0-746.1), cleft 
 palate (ICD-9: 749.0), cleft lip with or without cleft palate 
(ICD-9: 749.2-749.4), esophageal atresia (ICD-9: 750.3), 
anal atresia (ICD-9: 751.23-751.24), hypospadias (ICD-
9:752.6), any limb reduction defect (ICD-9: 755.2), cranio-
synostosis (ICD-9: 756.0), gastroschisis (ICD-9: 756.71), 
and omphalocele (ICD-9: 756.70). Some defects reported 
in other studies (for example, cystic kidney) could not 
be  evaluated in this analysis because they were not 
included in NBDPS.13
Development of priors
A bayesian approach requires specification of prior 
 distributions for each of the variables in the model used 
to estimate the potential association between risk of 
birth defect and use of SSRIs. These prior distributions 
are probabilistic summaries of beliefs about the true 
values of the unknown variables before assessment of 
new data. The bayesian approach allowed us to incor-
porate existing information on the association between 
each SSRI and the birth defect outcome of interest. Prior 
distributions were developed based on literature 
review. A systematic review identified six studies pub-
lished before 2010 that had available specific informa-
tion on SSRI-birth defect combinations (table 1).8-13
We created categories of birth defects based on those 
reports, which corresponded as closely as possible to 
the NBDPS birth defect categories (table 1).8-13 The 
approach used to summarize the information presented 
in these publications for each of the SSRI-birth defect 
combinations of interest depended on the number of 
available studies; to avoid duplication of cases in the 
current analysis, we did not include the results from the 
earlier NBDPS analysis.8  If one published assessment 
was only available, then the prior distribution for the 
log of the odds ratio relating the birth defect and use of 
SSRIs was assumed to be normal, with a mean given by 
the log odds ratio estimate reported in the study and 
variance defined using the corresponding reported con-
fidence interval. If two or more studies were identified, 
we used bayesian meta-analysis methods to summarize 
the results. The goal of the meta-analysis was to 
 produce an estimate of the log odds ratio relating the 
specific birth defect and SSRI across studies, taking into 
account the study specific estimates and their associ-
ated sampling errors. The assumed meta-analysis 
model included a term corresponding to the true under-
lying log odds ratio relating SSRI use and risk of birth 
defects and a collection of random study level effects.20 
All available information was included in developing 
the meta-analysis based prior estimates, including 
results indicating no association between risk of birth 
defects and SSRI use from other published studies. If no 
information other than the previous NBDPS analysis8 
was identified, then we assumed the log odds ratio 
relating birth defects and SSRI use to have a non- 
informative prior distribution, defined using a normal 
distribution with mean zero and a variance of 1000. 
Using this non-informative prior places virtually the 
entire weight in developing the bayesian estimates on 
the information contained in the full NBDPS data.
An alternative approach to this analysis would be to 
develop estimates of the association between SSRI con-
sumption and risk of birth defects using frequentist 
methods only focused on the 1997-2009 NBDPS data. 
These results could be summarized and then included 
as an additional point in a larger meta-analysis of avail-
able information. We chose the bayesian approach for 
two primary reasons. Firstly, we viewed the collection of 
information summarized by the meta-analysis as the 
state of current knowledge concerning potential associ-
ation between SSRIs and risk of birth defects and the 
NBDPS data as new information available to update that 
knowledge. This view is consistent with the bayesian 
updating paradigm as applied in this analysis. In addi-
tion, we believe that only utilizing summary values (for 
example, estimated odds ratios and their standard 
errors) from the NBDPS data would be an unnecessary 
sacrifice of information as opposed to utilizing the indi-
vidual level data informed by the meta-analysis priors.
bayesian analysis
We used a bayesian approach to develop estimates for a 
logistic regression model relating the log odds of a spe-
cific defect and the mother’s use of SSRIs (see supple-
mentary appendix 1). In addition to a term reflecting the 
log odds ratio relating birth defects and use of SSRIs, 
the model also included confounders selected a priori 
and obtained through the maternal interview: maternal 
race/ethnicity (non-Hispanic white versus other), 
maternal education (0-12 years versus >12 years), obe-
sity (body mass index <30 versus ≥30), and smoking 
(any smoking versus no smoking from one month 
before to the end of the first trimester). Although prior 
probabilities for the variable relating birth defect risk 
and use of SSRIs were developed, we assumed non-in-
formative priors for the odds ratios associated with 
maternal race/ethnicity, education, obesity, and smok-
ing in the logistic regression model. Posterior estimates 
for the model variables were developed using Markov 
Chain Monte Carlo methods. BUGS was used for the 
bayesian analyses.21
The primary results presented here were derived 
using an analysis based only on NBDPS participants 
who reported values for all the variables used in the 
logistic regression model. We also conducted sensitivity 
analyses focused on assessing the impact of not includ-
ing participants with missing information, including 
consideration of a potential association between being 
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missing and the unknown outcome. This analysis 
 utilized bayesian imputation for missing data both 
under an assumption that the missing information was 
missing at random and under plausible assumptions on 
mechanisms for informative missingness (see supple-
mentary appendix 1).
Results
A total of 38 009 women with births between 1997 
and 2009 were interviewed for the NBDPS. We 
excluded women reporting pre-existing diabetes 
(n=719), known use of teratogenic drugs (n=65), or 
depression, anxiety, bipolar disorder, or obsessive 
compulsive disorder but not reporting any antide-
pressant use (n=30). And, after excluding defects 
with no previous reported associations with SSRIs, 
the final analyses included 17 293 unexposed cases, 
659 cases exposed to citalopram, escitalopram, flu-
oxetine, paroxetine or sertraline, 9559 unexposed 
controls, and 298 controls that were exposed to one 
of these SSRIs (figure).
Sertraline was the most commonly used SSRI; 
approximately 40% of control mothers who reported 
use of an SSRI used sertraline (table 2 ). Although there 
was some difference in overall SSRI use by state, the 
distribution of the specific SSRIs was similar across the 
study sites. There was no difference in the age distribu-
tion among SSRI users except for sertraline, which was 
more often reported among older mothers. Reported 
use of citalopram and escitalopram started in 2000 and 
2002, respectively, and increased over time. Fluoxetine 
reports decreased over time, but not as much as parox-
etine use decreased, and sertraline use stayed relatively 
constant. There was no difference in the use of the spe-
cific SSRIs before or after 1 December 2006, the date the 
American College of Obstetricians and Gynecologists 
published their committee opinion on SSRI use in 
 pregnancy.22  23
In a bayesian analysis of the current NBDPS data that 
takes into account non-NBDPS individual drug-specific 
birth defect associations previously reported in the lit-
erature, no association with maternal use of citalopram 
or escitalopram monotherapy was found, except for a 
marginal association between citalopram and neural 
tube defects (table 3 ). For fluoxetine treatment, associ-
ations were seen for ventricular septal defects, right 
ventricular outflow tract obstruction cardiac defects, 
and craniosynostosis. Paroxetine had the most previ-
ously reported associations, and significant associa-
tions were observed for five of the seven defects 
assessed. Associations between paroxetine and 
 anencephaly, atrial septal defects, and right ventricular 
outflow tract obstruction cardiac defects found in other 
studies were confirmed in this independent dataset, 
and two other associations seen in the previous NBDPS 
analysis8 (gastroschisis and omphalocele) were again 
seen in this analysis. For sertraline, the most commonly 
used SSRI in our study, the findings for all five defects 
assessed were not significant.
A bayesian analysis using a non-informative prior 
(that is, assuming there were no previously published 
studies to help develop an informative prior), and 
Women interviewed (n=38 009)
Exclude cases with defects not included in 6 previously published analyses (n=8316)
No SSRIs
(n=34 843)
Citalopram
(n=129)
Escitalopram
(n=112)
Fluoxetine
(n=331)
Paroxetine
(n=214)
Sertraline
(n=440)
Multiple SSRIs
(n=56)
Fluvoxamine
(n=3)
Any SSRIs used from one month before conception through 1st trimester (n=1285)
No SSRIs
(n=26 852)
Cases
(n=17 293)
Controls
(n=9559)
Cases
(n=64)
Controls
(n=29)
Cases
(n=54)
Controls
(n=26)
Cases
(n=168)
Controls
(n=74)
Cases
(n=123)
Controls
(n=42)
Cases
(n=220)
Controls
(n=115)
Cases
(n=30)
Controls
(n=12)
Citalopram
(n=93)
Escitalopram
(n=80)
Fluoxetine
(n=242)
Paroxetine
(n=165)
Sertraline
(n=335)
Multiple SSRIs
(n=42)
Fluvoxamine
(n=1)
Unknown or not all medication
questions answered (n=261)
SSRI use reported (n=1624)Reported use of antidepressant
other than SSRI (n=467)
No antidepressant use
reported (n=34 843)
SSRIs used previous to 1 month before
conception or after 1st trimester
Excluded (n=814):
  Pre-existing diabetes (n=719)
  Teratogenic medications reported (n=65)
  Reported depression, anxiety, bipolar disorder, or obsessive
    compulsive disorder but no antidepressants (n=30)
Flow chart of participants through study
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 sensitivity analyses using bayesian methods in which 
missing data for confounders were replaced with 
imputed values showed similar results for most associ-
ations except for the association between citalopram 
and neural tube defects. The prior for that association 
was based on one cohort study, which found a higher 
odds ratio, and our logistic regression analysis without 
considering this prior study showed no association (see 
supplementary table).
discussion
Using data from the US National Birth Defects Preven-
tion Study (NBDPS), we confirmed previously reported 
associations between right ventricular outflow tract 
table 2 | Descriptive statistics of control mothers (n=9857) who reported periconceptional use of selective serotonin reuptake inhibitors (ssris), 
national birth Defects Prevention study, 1997-2009
variables
no (%) using ssris
any ssris Citalopram escitalopram Fluoxetine Paroxetine sertraline Multiple ssris
Total 298 (3.0) 29 (9.7) 26 (8.7) 74 (24.8) 42 (14.1) 115 (38.6) 12 (4.0)
Study site*:
 New Jersey 7 (1.2) 0 0 1 (14) 3 (43) 3 (43) 0
 Texas 17 (1.4) 1 (6) 1 (6) 3 (18) 2 (12) 9 (53) 1 (6)
 California 24 (2.1) 1 (4) 2 (8) 8 (33) 2 (8) 8 (33) 3 (13)
 Georgia 23 (2.2) 3 (13) 1 (4) 8 (35) 1 (4) 9 (39) 1 (4)
 New York 21 (2.5) 2 (10) 1 (5) 4 (19) 5 (24) 8 (38) 1 (5)
 Arkansas 43 (3.5) 3 (7) 4 (9) 11 (26) 2 (5) 20 (47) 3 (7)
 North Carolina 28 (3.6) 2 (7) 5 (18) 4 (14) 5 (18) 12 (43) 0
 Massachusetts 42 (3.6) 5 (12) 2 (5) 12 (29) 7 (17) 16 (38) 0
 Iowa 42 (3.9) 3 (7) 5 (12) 9 (21) 10 (24) 13 (31) 2 (5)
 Utah 51 (6.1) 9 (18) 5 (10) 14 (27) 5 (10) 17 (33) 1 (2)
Maternal age (years):
 <20 14 (1.4) 2 (14) 0 4 (29) 3 (21) 5 (36) 0
 20-24 55 (2.4) 5 (9) 4 (7) 13 (24) 7 (13) 21 (38) 5 (9)
 25-29 81 (3.0) 6 (7) 5 (6) 23 (28) 14 (17) 31 (38) 2 (2)
 30-34 100 (4.0) 12 (12) 12 (12) 23 (23) 11 (11) 38 (38) 4 (4)
 35-39 41 (3.6) 3 (7) 5 (12) 9 (22) 5 (12) 18 (44) 1 (2)
 ≥40 5 (3.0) 1 (20) 0 2 (40) 2 (40) 0 0
Maternal race/ethnicity†:
 Hispanic 21 (0.9) 0 1 (5) 8 (38) 3 (14) 8 (38) 1 (5)
 Non-Hispanic black 13 (1.2) 1 (8) 0 3 (23) 1 (8) 6 (46) 2 (15)
 Other 15 (2.1) 3 (20) 1 (7) 3 (20) 2 (13) 6 (40) 0
 Non-Hispanic white 249 (4.4) 25 (10) 24 (10) 60 (24) 36 (14) 95 (38) 9 (4)
Maternal education (years)†:
 0-8 4 (0.8) 0 0 1 (25) 1 (25) 2 (50) 0
 9-11 27 (2.4) 2 (7) 0 7 (26) 7 (26) 9 (33) 2 (7)
 12 66 (2.8) 3 (5) 6 (9) 21 (32) 9 (14) 24 (36) 3 (5)
 13-15 98 (3.8) 13 (13) 9 (9) 19 (19) 16 (16) 37 (38) 4 (4)
 ≥16 102 (3.3) 11 (11) 11 (11) 25 (25) 9 (9) 43 (42) 3 (3)
Prepregnancy maternal body mass index (kg/m2)†:
 <18.5 8 (1.6) 1 (13) 0 2 (25) 3 (38) 2 (25) 0
 18.5-24.9 162 (3.2) 13 (8) 14 (9) 41 (25) 24 (15) 65 (40) 5 (3)
 25-29.9 67 (3.1) 11 (16) 5 (7) 18 (27) 5 (7) 23 (34) 5 (7)
 ≥30 60 (3.7) 4 (7) 7 (12) 12 (20) 10 (17) 25 (42) 2 (3)
Periconceptional maternal smoking:
 No 215 (2.7) 21 (10) 19 (9) 59 (27) 25 (12) 83 (39) 8 (4)
 Yes 82 (4.7) 8 (10) 7 (9) 14 (17) 17 (21) 32 (39) 4 (5)
Periconceptional maternal alcohol use:
 No 147 (2.4) 16 (11) 11 (7) 31 (21) 20 (14) 64 (44) 5 (3)
 Yes 149 (4.2) 13 (9) 14 (9) 42 (28) 22 (15) 51 (34) 7 (5)
Year of due date:
 1997-99 34 (2.0) 0 0 11 (32) 9 (26) 14 (41) 0
 2000-01 36 (2.2) 4 (11) 0 14 (39) 5 (14) 11 (31) 2 (6)
 2002-03 43 (2.8) 7 (16) 1 (2) 9 (21) 6 (14) 17 (40) 3 (7)
 2004-05 76 (4.5) 2 (3) 8 (11) 18 (24) 14 (18) 31 (41) 3 (4)
 2006-07 52 (3.1) 5 (10) 8 (15) 13 (25) 6 (12) 19 (37) 1 (2)
 2008-09 57 (3.6) 11 (19) 9 (16) 9 (16) 2 (4) 23 (40) 3 (5)
*Sites are statewide for Arkansas, Iowa, and Utah. All other sites are selected regions. Years included: Arkansas 1998-2009, California 1997-2009, Georgia 1997-2009, Iowa 1997-2009, 
Massachusetts 1997-2009, New Jersey 1998-2003, New York 1997-2002 and 2004-09, North Carolina 2003-09, Texas 1997-2009, and Utah 2003-09.
†Variables were recoded to dichotomous categories for adjusted analyses; non-Hispanic white versus other, 0-12 years education versus >12 years, body mass index <30 versus ≥30 kg/m2.
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obstruction cardiac defects in infants and maternal use 
of fluoxetine12 or paroxetine8 11 12  early in pregnancy, and 
between anencephaly8 11  or atrial septal defects9  in 
infants and maternal use of paroxetine. This analysis 
also confirmed associations between gastroschisis or 
omphalocele and paroxetine and between craniosynos-
tosis and fluoxetine that were reported in the analysis of 
an earlier subset of NBDPS data;8 however, these still 
require corroboration in an independent data source. 
It is reassuring that none of the five previously reported 
associations between sertraline and birth defects8 10-12 
were confirmed in this analysis, particularly since 
about 40% of women reporting use of an SSRI in early 
pregnancy used sertraline. In addition, we did not find 
support for nine other previously reported associations 
between maternal SSRI treatment and selected birth 
defects in the child.
Although our analysis strongly supports the validity 
of the associations that were observed, the increase in 
the absolute risks, if the associations are causal, is 
small. The two strongest posterior odds ratios were seen 
for maternal paroxetine treatment and anencephaly 
(3.2) or right ventricular outflow tract obstruction car-
diac defects (2.4) in the infant. If these associations are 
causal, the absolute risks in the children of women who 
are treated with paroxetine early in pregnancy would 
increase for anencephaly from 2 per 10 00024  to 7 per 
10 000, and for right ventricular outflow tract obstruc-
tion cardiac defects from 10 per 10 00025 to 24 per 
10 000. The absolute risks for these birth defects are 
still low.
This analysis confirms the need to assess the associa-
tion between specific SSRIs and specific birth defects 
rather than combining an entire drug class or heteroge-
neous group of birth defects. Although SSRIs are similar 
pharmacologically, there are chemical differences, and 
if any of them do have teratogenic activity, it may be 
completely unrelated to the inhibition of serotonin 
receptors. SSRIs also differ pharmacokinetically,26  and 
this could account for differences in teratogenic activ-
ity, whether or not the mechanism involved inhibition 
of serotonin receptors.27
limitations of this study
This analysis does not address whether the birth defect 
associations we observed were caused by maternal SSRI 
treatment, underlying maternal disease, or some other 
factor. Since there was no specific question on depres-
sion and we cannot identify all participants with 
untreated depression, there is the possibility of 
 confounding by indication.
A recent publication by Furu and colleagues 
 combined data from five Nordic countries.28  Some over-
lap occurred between the data included in this recent 
study and the three Nordic studies we included in our 
meta-analysis, but this study also included data from 
Norway and Iceland that is not included in our 
 analyses.10 12 13  Many of the associations we assessed for 
septal heart defects and right ventricular outflow tract 
obstruction cardiac defects showed similar risk esti-
mates in our analysis and the recent study. One clear 
different finding is the association reported by Furu and 
colleagues for anal atresia and sertraline that was also 
reported by Louik and colleagues but is not evident in 
the NBDPS data.11 28
Additional limitations of this analysis need to be 
acknowledged. Periconceptional exposure was based 
on maternal self report, with interviews conducted six 
weeks to 24 months after the expected date of delivery. 
However, Kwon and colleagues reported good concor-
dance between self report of antidepressants and 
claims data.29
We made 21 comparisons between exposure and out-
come using five different models, and it is possible that 
some statistically significant findings occurred owing to 
the occurrence of false positive associations expected 
with multiple comparisons.30  Another limitation is that 
the small numbers for some of the individual birth 
defects and some of the specific exposures resulted in 
unstable estimates. Finally, exposure ascertainment is 
known to be more complete when women are specifi-
cally asked about their use of drugs by name;31 the 
interview did not include a specific question about use 
of escitalopram.
strengths of this study
This analysis also has some important strengths. The 
bayesian analysis enabled consideration of evidence 
both for and against an association between use of 
SSRIs and risk of birth defects from previous epidemio-
logical studies in the analyses and used relatively 
homogenous and discrete classes of birth defects and 
SSRI monotherapy. As a result, our study provides 
strong evidence for the reproducibility and validity of 
the associations that were observed. The sensitivity 
assessment showed that missing data were unlikely to 
have affected the results. The association between 
SSRIs and heart defects is biologically plausible; 
Sadler27 has suggested that the association may be a 
result of the key role that the neurotransmitter  serotonin 
(5-hydroxytryptamine) plays in embryonic develop-
ment of the heart.
A major advantage of this analysis over some previ-
ous reports is the ability to assess individual SSRIs and 
individual birth defects, while accounting for earlier 
reported associations. Although the data are self 
reported, they do represent reported use of the medica-
tions and not just filling of the prescription. Approxi-
mately 30% of mothers stop taking SSRIs during 
pregnancy,32  and this might not be captured if we relied 
on prescription information or medical records, since 
prescriptions might have been filled but not taken after 
the pregnancy was recognized. We have previously 
used NBDPS data to show that antidepressant prescrip-
tion patterns have changed over time,5 making it more 
challenging to study these associations.
Our analyses of a large population based case- control 
dataset combined with prior odds ratios based on the 
literature allowed us to show and refine associations 
between maternal fluoxetine or paroxetine treatment 
during pregnancy and right ventricular outflow tract 
obstruction cardiac defects and between maternal use 
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of paroxetine and anencephaly or atrial septal defects. 
In contrast, we found no evidence to support 14 other 
previously reported associations between maternal 
SSRI use and birth defects. Continued scrutiny of the 
association between SSRIs and birth defects is war-
ranted, and additional studies of specific SSRI treat-
ments during pregnancy and birth defects are needed to 
enable women and their healthcare providers to make 
more informed decisions about treatment. Meanwhile, 
the current analysis can help guide healthcare provid-
ers and women to the safest options for treatment 
during early pregnancy to minimize the risk of major 
birth defects, while providing adequate treatment of 
maternal depression.
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Appendix table: Odds ratios for associations between 
selected SSRIs and birth defects using different statistical 
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